妊娠期HIV感染者接受异烟肼预防性治疗的安全性与有效性:基于关联人群数据的观察性研究
结果显示产前IPT暴露与不良妊娠结局风险降低相关(aOR 0.83),并降低结核病风险约30%(aHR 0.71),在CD4计数≤350 cells/μL的女性中保护作用更明显(aHR 0.51)。
要点
- 产前IPT与不良妊娠结局风险降低相关,尤其孕早期后启动者。
- IPT降低妊娠期HIV感染者结核病风险约30%。
- CD4≤350 cells/μL者从IPT中获益更大。
核心结论
- 产前异烟肼预防性治疗对妊娠期HIV感染者安全性令人放心,且在CD4计数≤350 cells/μL的女性中对结核病的保护作用最大。
研究设计与样本
- 妊娠结局采用逻辑回归分析,母亲结局采用含时间更新IPT暴露的比例风险模型。
临床怎么用
- 妊娠期HIV感染者可考虑产前IPT,尤其CD4计数≤350 cells/μL者获益更明显。
- IPT启动时机需权衡,孕早期后启动与更低的不良妊娠结局风险相关。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Isoniazid preventive therapy (IPT) is widely used to protect against tuberculosis (TB) in people living with human immunodeficiency virus (HIV). Data on the safety and efficacy of IPT in pregnant women living with HIV (PWLHIV) are mixed. We used an individual-level, population-wide health database to examine associations between antenatal IPT exposure and adverse pregnancy outcomes, maternal TB, all-cause mortality, and liver injury during pregnancy through 12 months postpartum. METHODS: We used linked routine electronic health data generated in the public sector of the Western Cape, South Africa, to define a cohort of PWLHIV on antiretroviral therapy. Pregnancy outcomes were assessed using logistic regression; for maternal outcomes we applied a proportional hazards model with time-updated IPT exposure. RESULTS: Of 43 971 PWLHIV, 16.6% received IPT. Women who received IPT were less likely to experience poor pregnancy outcomes (adjusted odds ratio [aOR], 0.83 [95% confidence interval {CI}, .78-.87]); this association strengthened with IPT started after the first trimester compared with none (aOR, 0.71 [95% CI, .65-.79]) or with first-trimester exposure (aOR, 0.64 [95% CI, .55-.75]). IPT reduced the risk of TB by approximately 30% (aHR, 0.71 [95% CI, .63-.81]; absolute risk difference, 1518/100 000 women). The effect was modified by CD4 cell count with protection conferred if CD4 count was ≤350 cells/μL (aHR, 0.51 [95% CI, .41-.63]) vs 0.93 [95% CI, .76-1.13] for CD4 count >350 cells/µL). CONCLUSIONS: This analysis of programmatic data is reassuring regarding the safety of antenatal IPT, with the greatest benefits against TB disease observed in women with CD4 count ≤350 cells/μL.
引用
- Kalk E, Heekes A, Mehta U, et al. Safety and Effectiveness of Isoniazid Preventive Therapy in Pregnant Women Living with Human Immunodeficiency Virus on Antiretroviral Therapy: An Observational Study Using Linked Population Data. Clin Infect Dis. 2020. PMID: 31900473. doi:10.1093/cid/ciz1224
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。